search
Back to results

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

Primary Purpose

Overweight, Obesity

Status
Completed
Phase
Not Applicable
Locations
Tunisia
Study Type
Interventional
Intervention
Tea infusion
Sponsored by
Laouani Aicha
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overweight focused on measuring Medicinal plants, Anti-lipidimic agents, Infusion

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Males and females age range of 18 and 75 years BMI >25 kg/ m^2 Exclusion Criteria: Hypertension Diabetes Asthma Smoking Professional athletic Pregnancy and breast feeding Participant with medical or psychiatric disorder or chronic pathology, Participant with eating disorder, food allergies. Participant with a history of cardiovascular disease, Participant with medication known to affect lipid metabolism, Participant with major gastrointestinal problems.

Sites / Locations

  • Faculty of Medicine of Sousse, 4000 Tunisia

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Experimental 1: low dose group

Experimental 2 : high dose group

Arm Description

Tea infusion which contain 5 mg of flavonoids, (low dose of flavonoids treatment quantification) oral administration , once daily.

Tea infusion which contain 20 mg of flavonoids, ( high dose of flavonoids Treatment quantification) oral administration , once daily .

Outcomes

Primary Outcome Measures

Change in serum Triglycerides (TG) levels
To evaluate the efficacy of 20 mg of flavonoids in reducing serum TG compared with low dose group ( 5 mg of flavonoids) after 10 days administration .
Change in serum High Density Lipoprotein Cholesterol (HDL-C) levels
To evaluate the efficacy of 20 mg of flavonoids in increasing HDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration
Change in Total Cholesterol ( TC) levels
To evaluate the efficacy of 20 mg of flavonoids in reducing TC levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration.
Change in Low Density Lipoprotein Cholesterol (LDL-C) levels
To evaluate the efficacy of 20 mg of flavonoids in reducing LDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration

Secondary Outcome Measures

no change from baseline in Alkaline phosphatase levels
no change from baseline in Aspartate aminotransferase levels.
no change from baseline in Alanine aminotransferase levels.
no change from baseline in gamma-glutamyltransferase levels.
no change from baseline in Albumin levels .
no change from baseline in total bilirubin levels
no change from baseline in direct bilirubin levels
no change from baseline in urea levels
no change from baseline in creatinine levels
no change from baseline in fasting blood glucose levels
no change from baseline in Red blood cells levels
no change from baseline in White blood cells levels
no change from baseline in Hemoglobin levels
no change from baseline in Hematocrit levels
no change from baseline in Platelets levels
no change from baseline in Hemodynamic indicators: heart rate and blood pressure : systolic blood pressure and diastolic blood pressure
Adverse events
Adverse events reported

Full Information

First Posted
April 11, 2023
Last Updated
April 21, 2023
Sponsor
Laouani Aicha
Collaborators
Faculty of Medicine, Sousse, Centre Hôpital Universitaire Farhat Hached, Université de Sousse, University of Tsukuba
search

1. Study Identification

Unique Protocol Identification Number
NCT05824039
Brief Title
Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.
Official Title
Safety and Efficacy of the Short Daily Administration of Nitraria Retusa Extract in Overweight and Obese Participants. .
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
March 20, 2021 (Actual)
Primary Completion Date
April 8, 2022 (Actual)
Study Completion Date
April 8, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Laouani Aicha
Collaborators
Faculty of Medicine, Sousse, Centre Hôpital Universitaire Farhat Hached, Université de Sousse, University of Tsukuba

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this randomized , double -blind clinical trial is to evaluate the efficacy and safety of a daily administration of Nitraria retusa extract in overweight and obese participants, during 10 days.
Detailed Description
Medicinal plants are widely used for their accessibility, safety and effectiveness and may be an excellent alternative strategy for developing future drugs with minor adverse effects. Several studies concerning the potential of bioactive components in plants and food products and their link to many diseases including, diabetes, cardiovascular disease and obesity. Nitraria retusa is a salt-tolerant plant that belongs to the Nitrariaceae family. It is particularly distributed in Asia, China, North Africa, Russia and Europe.It grows in the southern part of Tunisia and it is locally known as Ghardaq. The leaves serve as supplement for the tea and are used as poultice. Fresh leaves of Nitraria retusa have been used in traditional medicine in case of poisoning, upset stomach, ulcers, gastritis, enteritis, heartburn, colitis, and colonic abdominal pain. Moreover, anticancer, antioxidant, antiviral and antimicrobial activities of N. retusa have been reported .Several reports evinced that the leaf of Nitraria retusa contains high amounts of tannins, alkaloids, steroids and flavonoids, which could be responsible for its beneficial effects . Previous studies have demonstrated the effect of Nitraria retusa extract in obese mice against high fat diet through lowering glucose and triglycerides and the enhancement of the lipid metabolism in liver. The purpose of this study was to evaluate the efficacy and safety of short daily administration of Nitraria retusa extract in lipid profile in overweight and obese patients, during 10 days. This study will be carried out in 2 departments: the laboratory of biophysics of the Faculty of Medicine of Sousse and Endocrinology and diabetology of CHU Farhat Hached Sousse ,Tunisia. At day 0 and day 10 all the population will benifit of biological assessment which include: Biochimical parameters Complete lipid profile (Total Cholesterol (T-C), High-density Lipoprotein (HDL) Low-density Lipoprotein (LDL) and Triglycerides( TG) . Blood sugar Liver Function Test : Alkaline phosphatase (ALP), gamma-glutamyltransferase (G-GT), albumin, Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total ( TB) and direct bilirubin (DB). Renal Function Test : Serum Creatinine, urea Inflammatory assessment: Reactive protein C Hematological parameters : (Red blood cells (RBC), White blood cell (WBC), Platelet, Hemoglobin and Hematocrit). All Population will be randomized :Participant will be assigned to one of two treatments (low dose flavonoids or high dose flavonoids ). The diatry supplement :Nitraria retusa infusion will be prescribed at a quantity of powder which contained 5 mg of flavonoids or which contained 20 mg of flavonoids , added to 100 ml of boiling water and will be taken once a day at a bed time for 10 consecutive days. Statistical analysis Data entry and analysis will be performed using SPSS 22.0 for Windows(IBM Corp., NY, USA ). Results will be considered significant at p < 0.05 Normal distributions of the data will be assessed by Shapiro-Wilk test. Within-group differences in the biological parameters before and after the intervention will be compared using paired t-test when data are normally distributed and Wilcoxon Signed Rank Test when data are not normaly distrubuted. Between-group differences (low dose vs high dose) in the parameters will be assessed by independent samples t-test (parametric and equal variances), Welch's t-test (unequal variances) and Mann-Whitney U test (nonparametric)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity
Keywords
Medicinal plants, Anti-lipidimic agents, Infusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
98 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental 1: low dose group
Arm Type
Experimental
Arm Description
Tea infusion which contain 5 mg of flavonoids, (low dose of flavonoids treatment quantification) oral administration , once daily.
Arm Title
Experimental 2 : high dose group
Arm Type
Experimental
Arm Description
Tea infusion which contain 20 mg of flavonoids, ( high dose of flavonoids Treatment quantification) oral administration , once daily .
Intervention Type
Dietary Supplement
Intervention Name(s)
Tea infusion
Intervention Description
Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
Primary Outcome Measure Information:
Title
Change in serum Triglycerides (TG) levels
Description
To evaluate the efficacy of 20 mg of flavonoids in reducing serum TG compared with low dose group ( 5 mg of flavonoids) after 10 days administration .
Time Frame
10 days
Title
Change in serum High Density Lipoprotein Cholesterol (HDL-C) levels
Description
To evaluate the efficacy of 20 mg of flavonoids in increasing HDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration
Time Frame
10 days
Title
Change in Total Cholesterol ( TC) levels
Description
To evaluate the efficacy of 20 mg of flavonoids in reducing TC levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration.
Time Frame
10 days
Title
Change in Low Density Lipoprotein Cholesterol (LDL-C) levels
Description
To evaluate the efficacy of 20 mg of flavonoids in reducing LDL-C levels compared with low dose group ( 5 mg of flavonoids) after 10 days administration
Time Frame
10 days
Secondary Outcome Measure Information:
Title
no change from baseline in Alkaline phosphatase levels
Time Frame
10 days
Title
no change from baseline in Aspartate aminotransferase levels.
Time Frame
10 days
Title
no change from baseline in Alanine aminotransferase levels.
Time Frame
10 days
Title
no change from baseline in gamma-glutamyltransferase levels.
Time Frame
10 days
Title
no change from baseline in Albumin levels .
Time Frame
10 days
Title
no change from baseline in total bilirubin levels
Time Frame
10 days
Title
no change from baseline in direct bilirubin levels
Time Frame
10 days
Title
no change from baseline in urea levels
Time Frame
10 days
Title
no change from baseline in creatinine levels
Time Frame
10 days
Title
no change from baseline in fasting blood glucose levels
Time Frame
10 days
Title
no change from baseline in Red blood cells levels
Time Frame
10 days
Title
no change from baseline in White blood cells levels
Time Frame
10 days
Title
no change from baseline in Hemoglobin levels
Time Frame
10 days
Title
no change from baseline in Hematocrit levels
Time Frame
10 days
Title
no change from baseline in Platelets levels
Time Frame
10 days
Title
no change from baseline in Hemodynamic indicators: heart rate and blood pressure : systolic blood pressure and diastolic blood pressure
Time Frame
10 days
Title
Adverse events
Description
Adverse events reported
Time Frame
10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males and females age range of 18 and 75 years BMI >25 kg/ m^2 Exclusion Criteria: Hypertension Diabetes Asthma Smoking Professional athletic Pregnancy and breast feeding Participant with medical or psychiatric disorder or chronic pathology, Participant with eating disorder, food allergies. Participant with a history of cardiovascular disease, Participant with medication known to affect lipid metabolism, Participant with major gastrointestinal problems.
Facility Information:
Facility Name
Faculty of Medicine of Sousse, 4000 Tunisia
City
Sousse
ZIP/Postal Code
4002
Country
Tunisia

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21951288
Citation
Boubaker J, Bhouri W, Ben Sghaier M, Ghedira K, Dijoux Franca MG, Chekir-Ghedira L. Ethyl acetate extract and its major constituent, isorhamnetin 3-O-rutinoside, from Nitraria retusa leaves, promote apoptosis of human myelogenous erythroleukaemia cells. Cell Prolif. 2011 Oct;44(5):453-61. doi: 10.1111/j.1365-2184.2011.00772.x.
Results Reference
background
PubMed Identifier
22040460
Citation
Boubaker J, Bhouri W, Sghaier MB, Bouhlel I, Skandrani I, Ghedira K, Chekir-Ghedira L. Leaf extracts from Nitraria retusa promote cell population growth of human cancer cells by inducing apoptosis. Cancer Cell Int. 2011 Oct 31;11(1):37. doi: 10.1186/1475-2867-11-37.
Results Reference
background
PubMed Identifier
28198206
Citation
Chaabane M, Koubaa M, Soudani N, Elwej A, Grati M, Jamoussi K, Boudawara T, Ellouze Chaabouni S, Zeghal N. Nitraria retusa fruit prevents penconazole-induced kidney injury in adult rats through modulation of oxidative stress and histopathological changes. Pharm Biol. 2017 Dec;55(1):1061-1073. doi: 10.1080/13880209.2016.1278455.
Results Reference
background
PubMed Identifier
30391934
Citation
Hashempur MH, Mosavat SH, Heydari M, Shams M. Medicinal plants' use among patients with dyslipidemia: an Iranian cross-sectional survey. J Complement Integr Med. 2018 Nov 3;16(3):/j/jcim.2019.16.issue-3/jcim-2018-0101/jcim-2018-0101.xml. doi: 10.1515/jcim-2018-0101.
Results Reference
background
PubMed Identifier
25086370
Citation
Zar Kalai F, Han J, Ksouri R, Abdelly C, Isoda H. Oral administration of Nitraria retusa ethanolic extract enhances hepatic lipid metabolism in db/db mice model 'BKS.Cg-Dock7(m)+/+ Lepr(db/)J' through the modulation of lipogenesis-lipolysis balance. Food Chem Toxicol. 2014 Oct;72:247-56. doi: 10.1016/j.fct.2014.07.029. Epub 2014 Jul 30.
Results Reference
background
PubMed Identifier
30742925
Citation
Rjeibi I, Feriani A, Hentati F, Hfaiedh N, Michaud P, Pierre G. Structural characterization of water-soluble polysaccharides from Nitraria retusa fruits and their antioxidant and hypolipidemic activities. Int J Biol Macromol. 2019 May 15;129:422-432. doi: 10.1016/j.ijbiomac.2019.02.049. Epub 2019 Feb 8.
Results Reference
background
PubMed Identifier
24367387
Citation
Zar Kalai F, Han J, Ksouri R, El Omri A, Abdelly C, Isoda H. Antiobesity Effects of an Edible Halophyte Nitraria retusa Forssk in 3T3-L1 Preadipocyte Differentiation and in C57B6J/L Mice Fed a High Fat Diet-Induced Obesity. Evid Based Complement Alternat Med. 2013;2013:368658. doi: 10.1155/2013/368658. Epub 2013 Dec 3.
Results Reference
background

Learn more about this trial

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

We'll reach out to this number within 24 hrs